Evotaz

Shares of Bristol-Myers Squibb Co (NYSE: BMY) were boosted higher on Thursday after the company announced the European Commission approved its Evotaz for the treatment of HIV-1 in adults. Evotaz (atazanayir 300 mg and cobicistat 150 mg) is a daily tablet to be taken with other antiretroviral...